Bentley Pharmaceuticals Acquires New Product.TAMPA, Fla.--(BW HealthWire)--June 3, 1998--Bentley Pharmaceuticals Inc. (AMEX AMEX See: American Stock Exchange :BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol) BNT Boston Naming Test (psychology) BNT Bermuda National Trust BNT Bulgarian National TV BNT Broadband Network Termination BNT Binary File Transfer ) Wednesday announced the purchase of the product and trademark Relaxibys, in Spain, by its subsidiary Laboratorios Belmac S.A., from Econature. Relaxibys is a time tested, effective combination medication (consisting of carisoprodol and paracetamol paracetamol see acetaminophen. acetaminophen, paracetamol an analgesic and antipyretic drug in dogs. It is contraindicated for cats because of serious side-effects which include intravascular hemolysis, methemoglobinemia and hepatic necrosis. ), which is prescribed for the treatment of muscle spasm muscle spasm n. Persistent increased tension and shortness in a muscle or group of muscles that cannot be released voluntarily. muscle spasm, n and pain. Carisoprodol is a rapid acting muscle relaxant muscle relaxant an agent that specifically aids in reducing muscle tone. Most such agents inhibit the transmission of nerve impulses at the somatic neuromuscular junctions. They include tubocurarine, gallamine, pancuronium, succinylcholine and decamethonium bromide. which produces its result through its effect on the nervous system. Paracetamol is added for pain relief. Chairman and Chief Executive Officer Jim Murphy commented: "The acquisition of Relaxibys is another important step in our commitment to grow in the Spanish market through the acquisition of product registrations. We will continue to seek other opportunities to add registered, branded and well-known products to our Spanish portfolio. "According to IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. , the Spanish market for this category of products, in which we will compete, is approximately $10 million and has grown at a rate of 15 percent over the past year. We anticipate that moderate promotion will enhance sales and provide additional income to the company." Bentley Pharmaceuticals is an emerging international pharmaceutical company that leverages the competitive advantage of it's Spanish manufacturing facility with drug delivery technology to provide treatment for cardiovascular, gastrointestinal, neurological and infectious diseases. -0- Safe Harbor Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements which are not historical facts contained in the news release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, regulatory approval processes, the impact of competitive products or pricing, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in the company's filing with the Securities and Exchange Commission.
CONTACT: Kinexsys, Newport Beach, Calif.
Timothy R. Forstrom, 714/520-7507
or
Bentley Pharmaceuticals Inc., Tampa
Elaine Melia, 813/286-4401
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion